Mar 15 |
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
|
Mar 14 |
UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
|
Mar 14 |
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 14 |
UroGen Pharma reports mixed Q4 results; initiates FY24 outlook
|
Mar 14 |
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
|
Mar 14 |
Earnings Scheduled For March 14, 2024
|
Mar 13 |
UroGen Pharma Q4 2023 Earnings Preview
|
Mar 8 |
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 4 |
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
|
Mar 1 |
UroGen falls as Teva seeks FDA nod for Jelmyto generic
|